vs
Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and Cytek Biosciences, Inc. (CTKB). Click either name above to swap in a different company.
Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $62.1M, roughly 1.2× Cytek Biosciences, Inc.). Bioceres Crop Solutions Corp. runs the higher net margin — -9.6% vs -70.9%, a 61.3% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs -16.8%). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs -8.4%).
Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
BIOX vs CTKB — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $77.6M | $62.1M |
| Net Profit | $-7.4M | $-44.1M |
| Gross Margin | 46.8% | 52.9% |
| Operating Margin | 9.3% | -9.0% |
| Net Margin | -9.6% | -70.9% |
| Revenue YoY | -16.8% | 8.1% |
| Net Profit YoY | -20.2% | -557.1% |
| EPS (diluted) | $-0.12 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $62.1M | ||
| Q3 25 | $77.6M | $52.3M | ||
| Q2 25 | — | $45.6M | ||
| Q1 25 | $60.6M | $41.5M | ||
| Q4 24 | $98.8M | $57.5M | ||
| Q3 24 | $93.3M | $51.5M | ||
| Q2 24 | — | $46.6M | ||
| Q1 24 | $84.0M | $44.9M |
| Q4 25 | — | $-44.1M | ||
| Q3 25 | $-7.4M | $-5.5M | ||
| Q2 25 | — | $-5.6M | ||
| Q1 25 | $-1.6M | $-11.4M | ||
| Q4 24 | $605.2K | $9.6M | ||
| Q3 24 | $-6.2M | $941.0K | ||
| Q2 24 | — | $-10.4M | ||
| Q1 24 | $9.8M | $-6.2M |
| Q4 25 | — | 52.9% | ||
| Q3 25 | 46.8% | 52.7% | ||
| Q2 25 | — | 52.3% | ||
| Q1 25 | 39.4% | 48.6% | ||
| Q4 24 | 42.0% | 58.5% | ||
| Q3 24 | 40.2% | 56.3% | ||
| Q2 24 | — | 54.6% | ||
| Q1 24 | 50.8% | 51.3% |
| Q4 25 | — | -9.0% | ||
| Q3 25 | 9.3% | -17.6% | ||
| Q2 25 | — | -23.3% | ||
| Q1 25 | 1.5% | -36.1% | ||
| Q4 24 | 14.5% | 5.2% | ||
| Q3 24 | 2.5% | -8.2% | ||
| Q2 24 | — | -18.3% | ||
| Q1 24 | 15.7% | -23.9% |
| Q4 25 | — | -70.9% | ||
| Q3 25 | -9.6% | -10.5% | ||
| Q2 25 | — | -12.2% | ||
| Q1 25 | -2.6% | -27.5% | ||
| Q4 24 | 0.6% | 16.8% | ||
| Q3 24 | -6.6% | 1.8% | ||
| Q2 24 | — | -22.4% | ||
| Q1 24 | 11.6% | -13.8% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.12 | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-0.02 | — | ||
| Q4 24 | $0.00 | — | ||
| Q3 24 | $-0.10 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $0.14 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $15.5M | $90.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $288.3M | $341.7M |
| Total Assets | $734.9M | $461.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $90.9M | ||
| Q3 25 | $15.5M | $93.3M | ||
| Q2 25 | — | $75.5M | ||
| Q1 25 | $38.5M | $95.3M | ||
| Q4 24 | $29.2M | $98.7M | ||
| Q3 24 | $32.3M | $162.3M | ||
| Q2 24 | — | $177.9M | ||
| Q1 24 | $16.4M | $168.8M |
| Q4 25 | — | $341.7M | ||
| Q3 25 | $288.3M | $378.6M | ||
| Q2 25 | — | $377.6M | ||
| Q1 25 | $345.0M | $379.6M | ||
| Q4 24 | $346.3M | $395.7M | ||
| Q3 24 | $346.0M | $385.5M | ||
| Q2 24 | — | $389.1M | ||
| Q1 24 | $348.5M | $392.6M |
| Q4 25 | — | $461.5M | ||
| Q3 25 | $734.9M | $494.9M | ||
| Q2 25 | — | $493.3M | ||
| Q1 25 | $798.2M | $482.6M | ||
| Q4 24 | $835.2M | $499.5M | ||
| Q3 24 | $827.3M | $491.2M | ||
| Q2 24 | — | $483.7M | ||
| Q1 24 | $836.1M | $492.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.4M | $-771.0K |
| Free Cash FlowOCF − Capex | — | $-1.8M |
| FCF MarginFCF / Revenue | — | -2.9% |
| Capex IntensityCapex / Revenue | — | 1.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-8.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-771.0K | ||
| Q3 25 | $14.4M | $-3.9M | ||
| Q2 25 | — | $108.0K | ||
| Q1 25 | $23.3M | $-125.0K | ||
| Q4 24 | $-5.4M | $2.0M | ||
| Q3 24 | $5.2M | $13.2M | ||
| Q2 24 | — | $6.2M | ||
| Q1 24 | $-17.4M | $4.0M |
| Q4 25 | — | $-1.8M | ||
| Q3 25 | — | $-4.6M | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-974.0K | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | — | $12.2M | ||
| Q2 24 | — | $5.2M | ||
| Q1 24 | — | $3.4M |
| Q4 25 | — | -2.9% | ||
| Q3 25 | — | -8.7% | ||
| Q2 25 | — | -3.2% | ||
| Q1 25 | — | -2.3% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 23.7% | ||
| Q2 24 | — | 11.0% | ||
| Q1 24 | — | 7.6% |
| Q4 25 | — | 1.6% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 2.0% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 2.3% | ||
| Q1 24 | — | 1.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -8.85× | 0.21× | ||
| Q3 24 | — | 14.05× | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.78× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIOX
Segment breakdown not available.
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
